Highlight News

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU

Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on Devyser’s patented next-generation sequencing library prep technology and provides targeted sequencing of 12 genes with a recognized connection to the development …

Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU Read More »

Discover Devyser CFTR 68

https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated with Cystic Fibrosis. List of mutations detected by Devyser CFTR 68 711+ 1G>T, 2043delG, 1677delTA, W1282X, R1283M, K710X, 3849+10kbC>T, 2789+5G>A, M1101K, G85E, 3905insT, 1525-1G>A, 2184delA, 3659delC, N1303K, 2184insA, 1812-1G->A, CFTRdele2,3, …

Discover Devyser CFTR 68 Read More »

Join our Q&A Poster viewings at the ESHG 2020 Virtual Conference!

The Q&A Poster viewing sessions at ESHG 2020 Virtual Conference will highlight two of our products: Devyser RHD, a non-invasive risk screening kit for RhD-negative mothers and Devyser Thalassemia, a single-tube NGS kit for Thalassemia detection. Devyser RHD Sunday, June 7th – 13.00 – 13.45 CEST P01.109.A: “A fast and non-invasive method for fetal RHD …

Join our Q&A Poster viewings at the ESHG 2020 Virtual Conference! Read More »